The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shamalov N.A.

Federal Center for Brain and Neurotechnologies

Khasanova D.R.

Interregional Clinical and Diagnostic Center;
Kazan State Medical University

Marchenko S.V.

Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

Soldatov M.A.

Center of the Brain Neurotechnologies

Azarova A.G.

Pskov Regional Clinical Hospital

Alekseeva T.P.

City Clinical Hospital named after S.S. Yudin

Alekseevich G.Yu.

Regional Clinical Hospital

Androfagina O.V.

Seredavin Samara Regional Clinical Hospital

Anishchenko L.I.

District Clinical Hospital

Antipova L.N.

Regional Clinical Hospital No. 2

Bezrukov I.E.

Krasnogorsk Hospital

Beketova E.M.

Samara City Clinical Hospital No. 1 named after N.I. Pirogov

Bitokov A.V.

Republican Clinical Multidisciplinary Center of High Medical Technologies

Bogolyubova I.V.

Hospital for War Veterans

Bulanov A.A.

Penza Regional Clinic Hospital named after N.N. Burdenko

Gerasimova A.V.

Republican Hospital No. 1 — National Center of Medicine named after M.E. Nikolaev

Gutsalyuk A.G.

City Clinical Hospital named after A.K. Eramishantsev

Demina S.A.

City Clinical Hospital No. 14

Demin T.V.

Interregional Clinical and Diagnostic Center

Dyachenko N.A.

Regional Medical Clinic Hospital of Emergency Medical Care named after N.S. Karpovich

Diudin A.V.

City Hospital No. 26

Zhuravlev M.N.

Regional Clinical Hospital No. 2

Zakaryaeva A.R.

Municipal Clinical Hospital named after V.V. Veresaev

Zinoveva N.P.

City Clinical Hospital No. 1

Ziborova S.S.

Novokuznetsk City Clinical Hospital No. 1 named after G.P. Kurbatov

Ismailova K.A.

Pirogov Russian National Research Medical University

Kirpicheva S.V.

Clinical Hospital No. 2

Kolerova I.V.

Pirogov City Clinical Hospital No. 1

Korobeynikov I.V.

Regional Clinical Hospital

Kuzmin E.L.

Novgorod Regional Clinical Hospital

Kulesh A.A.

City Clinical Hospital No. 4

Kuliev R.R.

City Clinical Hospital named after A.K. Eramishantsev

Lukyanov A.L.

City Clinical Hospital No. 31 named after Academician G.M. Savelyeva

Maksimov V.I.

Republican Hospital named after V.A. Baranov, Petrozavodsk

Mandrov S.V.

Regional Clinical Hospital

Moldavskaya I.V.

Kuzbass Clinical Cardiology Center named after L.S. Barbarash

Mongush Kh.D.

Republican Hospital No. 1, Kyzyl

Murtazalieva D.M.

Municipal Clinical Hospital named after V.V. Veresaev

Naydenova V.V.

Togliatti City Clinical Hospital No 2 named after V.B. Banykina

Nikolaev S.V.

Republican Clinical Hospital No. 4

Nesterova V.N.

Regional Clinical Hospital

Prudius E.P.

Rostov Regional Clinical Hospital

Pustynnikov Ya.A.

Mozhaiskaya Hospital

Ramazanov G.R.

Sklifosovsky Institute for Emergency Medicine

Saskin V.A.

First City Clinical Hospital named after E.E. Volosevich

Strautmanis E.A.

City Clinical Emergency Hospital No. 1

Teliatnik Yu.A.

Research Institute — Regional Clinical Hospital No. 1 named after S.V. Ochapovsky

Khalo N.V.

Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon

Chirkov A.N.

Orenburg Regional Clinical Hospital named after V.I. Voinov

Shevchenko E.V.

Sklifosovsky Institute for Emergency Medicine

Marskaya N.A.

Federal Center for Brain and Neurotechnology

Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study

Authors:

Shamalov N.A., Khasanova D.R., Marchenko S.V., Soldatov M.A., Azarova A.G., Alekseeva T.P., Alekseevich G.Yu., Androfagina O.V., Anishchenko L.I., Antipova L.N., Bezrukov I.E., Beketova E.M., Bitokov A.V., Bogolyubova I.V., Bulanov A.A., Gerasimova A.V., Gutsalyuk A.G., Demina S.A., Demin T.V., Dyachenko N.A., Diudin A.V., Zhuravlev M.N., Zakaryaeva A.R., Zinoveva N.P., Ziborova S.S., Ismailova K.A., Kirpicheva S.V., Kolerova I.V., Korobeynikov I.V., Kuzmin E.L., Kulesh A.A., Kuliev R.R., Lukyanov A.L., Maksimov V.I., Mandrov S.V., Moldavskaya I.V., Mongush Kh.D., Murtazalieva D.M., Naydenova V.V., Nikolaev S.V., Nesterova V.N., Prudius E.P., Pustynnikov Ya.A., Ramazanov G.R., Saskin V.A., Strautmanis E.A., Teliatnik Yu.A., Khalo N.V., Chirkov A.N., Shevchenko E.V., Marskaya N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12‑2): 43‑53

DOI: 10.17116/jnevro202512512243

Read: 968 times

Download PDF (RU)
Contact the author
Table of contents

THROMBOLYTIC THERAPY FOR ISCHEMIC STROKE WITH REVELISE: RESULTS OF A TWO-YEAR FOLLOW-UP IN THE INTERNATIONAL PRIMA STUDY
THROMBOLYTIC THERAPY FOR ISCHEMIC STROKE WITH REVELISE: RESULTS OF A TWO-YEAR FOLLOW-UP IN THE INTERNATIONAL PRIMA STUDY

To cite this article:

Shamalov NA, Khasanova DR, Marchenko SV, et al. . Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12‑2):43‑53. (In Russ.)
https://doi.org/10.17116/jnevro202512512243

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sequential use of botu­linum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85
Central nervous system invo­lvement in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):124-129
Adju­vant pharmacological modu­lation with Cyto­flavin in reha­bilitation at stages 2—3 in patients with acute cere­bral insu­fficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Comparison of fluoroscopy and intracardiac echo­cardiography for control of endo­vascular closure of patent fora­men ovale. Russian Cardiology Bulletin. 2025;(1):64-69
Biosimilars of rani­bizumab in reti­nal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98
Cere­brolysin with repe­rfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):84-98
Prediction of mortality in severe ischemic stroke during COVID-19 in patients with multiorgan dysfunction. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):120-127
Abstract:

OBJECTIVE

The study aimed to evaluate the efficacy and safety of Revelise (alteplase), a Russian medicinal product used as thrombolytic therapy (TLT) to treat ischemic stroke (IS) in real-world practice.

MATERIAL AND METHODS

A total of 2202 patients with IS were included in the study. The mean age was 68 years, with 20% of patients aged 80 years or older. Of the patients, 53.6% were men and 46.4% were women; 233 (10.6%) patients with large vessel occlusion underwent staged reperfusion. The most common comorbidities were hypertension (96%), chronic heart failure (57.3%), coronary artery disease (56.9%), and cardiac arrhythmias (33.8%). Nearly one-third (28.9%) of patients received antiplatelet agents before TLT, whereas 4.7% received anticoagulants. The mean NIHSS score for the entire study population was 10, and 11.6% had disabling symptoms with a NIHSS score< 5. Symptomatic hemorrhagic transformation was determined using the ECASS 3 criteria.

RESULTS

A substantial reduction in neurological deficit was reported within one day, which differed significantly from the previous value (p< 0.001). Twenty-four hours after TLT, 42.8% of patients demonstrated a decrease in their NIHSS score by ≥4. The hospital mortality rate was 8.2%. Symptomatic hemorrhagic transformation developed in 2.5% of patients. Favorable outcomes (mRS 0—2) were reported in 49.9% of patients at discharge and 66.4% of patients 90 days after TLT.

CONCLUSION

The obtained results confirm the high efficacy and safety of Revelise in patients with IS. The wide practical use in various patient groups is justified by an up-to-date patient selection algorithm. This includes patients aged 80 years and older with minor stroke (NIHSS score< 5) who receive treatment with antiplatelet agents or anticoagulants, as well as staged reperfusion. The obtained results are consistent with those of previously published studies with a similar design.

Keywords:

ischemic stroke
thrombolytic therapy
reperfusion therapy
systemic thrombolysis
alteplase
Revelisa
biosimilar
rt-PA
bridging
staged reperfusion

Authors:

Shamalov N.A.

Federal Center for Brain and Neurotechnologies

Khasanova D.R.

Interregional Clinical and Diagnostic Center;
Kazan State Medical University

Marchenko S.V.

Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

Soldatov M.A.

Center of the Brain Neurotechnologies

Azarova A.G.

Pskov Regional Clinical Hospital

Alekseeva T.P.

City Clinical Hospital named after S.S. Yudin

Alekseevich G.Yu.

Regional Clinical Hospital

Androfagina O.V.

Seredavin Samara Regional Clinical Hospital

Anishchenko L.I.

District Clinical Hospital

Antipova L.N.

Regional Clinical Hospital No. 2

Bezrukov I.E.

Krasnogorsk Hospital

Beketova E.M.

Samara City Clinical Hospital No. 1 named after N.I. Pirogov

Bitokov A.V.

Republican Clinical Multidisciplinary Center of High Medical Technologies

Bogolyubova I.V.

Hospital for War Veterans

Bulanov A.A.

Penza Regional Clinic Hospital named after N.N. Burdenko

Gerasimova A.V.

Republican Hospital No. 1 — National Center of Medicine named after M.E. Nikolaev

Gutsalyuk A.G.

City Clinical Hospital named after A.K. Eramishantsev

Demina S.A.

City Clinical Hospital No. 14

Demin T.V.

Interregional Clinical and Diagnostic Center

Dyachenko N.A.

Regional Medical Clinic Hospital of Emergency Medical Care named after N.S. Karpovich

Diudin A.V.

City Hospital No. 26

Zhuravlev M.N.

Regional Clinical Hospital No. 2

Zakaryaeva A.R.

Municipal Clinical Hospital named after V.V. Veresaev

Zinoveva N.P.

City Clinical Hospital No. 1

Ziborova S.S.

Novokuznetsk City Clinical Hospital No. 1 named after G.P. Kurbatov

Ismailova K.A.

Pirogov Russian National Research Medical University

Kirpicheva S.V.

Clinical Hospital No. 2

Kolerova I.V.

Pirogov City Clinical Hospital No. 1

Korobeynikov I.V.

Regional Clinical Hospital

Kuzmin E.L.

Novgorod Regional Clinical Hospital

Kulesh A.A.

City Clinical Hospital No. 4

Kuliev R.R.

City Clinical Hospital named after A.K. Eramishantsev

Lukyanov A.L.

City Clinical Hospital No. 31 named after Academician G.M. Savelyeva

Maksimov V.I.

Republican Hospital named after V.A. Baranov, Petrozavodsk

Mandrov S.V.

Regional Clinical Hospital

Moldavskaya I.V.

Kuzbass Clinical Cardiology Center named after L.S. Barbarash

Mongush Kh.D.

Republican Hospital No. 1, Kyzyl

Murtazalieva D.M.

Municipal Clinical Hospital named after V.V. Veresaev

Naydenova V.V.

Togliatti City Clinical Hospital No 2 named after V.B. Banykina

Nikolaev S.V.

Republican Clinical Hospital No. 4

Nesterova V.N.

Regional Clinical Hospital

Prudius E.P.

Rostov Regional Clinical Hospital

Pustynnikov Ya.A.

Mozhaiskaya Hospital

Ramazanov G.R.

Sklifosovsky Institute for Emergency Medicine

Saskin V.A.

First City Clinical Hospital named after E.E. Volosevich

Strautmanis E.A.

City Clinical Emergency Hospital No. 1

Teliatnik Yu.A.

Research Institute — Regional Clinical Hospital No. 1 named after S.V. Ochapovsky

Khalo N.V.

Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon

Chirkov A.N.

Orenburg Regional Clinical Hospital named after V.I. Voinov

Shevchenko E.V.

Sklifosovsky Institute for Emergency Medicine

Marskaya N.A.

Federal Center for Brain and Neurotechnology

Received:

30.09.2025

Accepted:

02.10.2025

Close metadata

References:

  1. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(10):973-1003. https://doi.org/10.1016/S1474-4422(24)00369-7
  2. IgnatyevaVI, VoznyukIA, ShamalovNA, et al. Social and economic burden of stroke In Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8-2):5-15. (In Russ.). https://doi.org/10.17116/jnevro20231230825
  3. Clinical guidelines «Ischemic stroke and transient ischemic attack in adults». 2024. Accessed September 24, 2025 (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/814_1
  4. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.  https://doi.org/10.1016/S0140-6736(04)15692-4
  5. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. https://doi.org/10.1056/NEJMoa0804656
  6. Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018;379(7):611-622.  https://doi.org/10.1056/NEJMoa1804355
  7. Thomalla G, Boutitie F, Ma H, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet. 2020;396(10262):1574-1584. https://doi.org/10.1016/S0140-6736(20)32163-2
  8. Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394(10193):139-147.  https://doi.org/10.1016/S0140-6736(19)31053-0
  9. You S, Saxena A, Wang X, et al. Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis. Stroke Vasc Neurol. 2018;3(1):22-27.  https://doi.org/10.1136/svn-2017-000106
  10. Tsivgoulis G, Goyal N, Katsanos AH, et al. Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity. Eur J Neurol. 2020;27(6):1039-1047. https://doi.org/10.1111/ene.14199
  11. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-1935. https://doi.org/10.1016/S0140-6736(14)60584-5
  12. Bluhmki E, Danays T, Biegert G, et al. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data. Stroke. 2020;51(8):2322-2331. https://doi.org/10.1161/STROKEAHA.119.028396
  13. Tsivgoulis G, Katsanos AH, Zand R, et al. Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. J Neurol. 2017;264(6):1227-1235. https://doi.org/10.1007/s00415-017-8520-1
  14. Jeong HG, Kim BJ, Yang MH, et al. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. Neurology. 2016;87(10):996-1002. https://doi.org/10.1212/WNL.0000000000003083
  15. Frol S, Sagris D, Pretnar Oblak J, et al. Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature. Front Neurol. 2021;12:666086. https://doi.org/10.3389/fneur.2021.666086
  16. Reed BR, Chen AB, Tanswell P, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost. 1990;64(2):276-280. 
  17. Fonseca GM, Padiglioni AC, de la Ossa NP, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):1163. https://doi.org/10.1177/2396987321989865
  18. Mead GE, Sposato LA, Sampaio Silva G, et al. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. Int J Stroke. 2023;18(5):499-531.  https://doi.org/10.1177/17474930231156753
  19. Muruet W, Rudd A, Wolfe CDA, Douiri A. Long-Term Survival After Intravenous Thrombolysis for Ischemic Stroke: A Propensity Score-Matched Cohort With up to 10-Year Follow-Up. Stroke. 2018;49(3):607-613.  https://doi.org/10.1161/STROKEAHA.117.019889
  20. General characteristics of the medicinal product Reveliza LP-No. (004035)-(RG-RU) dated 181223 Accessed 24.09.2025. https://www.generium.ru/products/reveliza-mnn-alteplaza/
  21. Pravila provedeniya issledovanij biologicheskikh lekarstvennykh sredstv Evrazijskogo ekonomicheskogo soyuza: Reshenie Soveta Evrazijskoj ekonomicheskoj komissii No. 89 ot 03.11.2016. M., 2016. (In Russ.). Accessed Sept 24, 2025. https://www.garant.ru/products/ipo/prime/doc/71446406
  22. Gusarova VD, Pantyushenko MS, Simonov VM, et al. Physico-Chemicaland Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products. BIOpreparaty. Profilaktika, diagnostika, lechenie 2019;19(1):39-49. (In Russ.). https://doi.org/10.30895/2221-996X-2019-19-1-39-49
  23. KokorinVA, MarkovaOA, GordeevIG, et al. Comparative safety and efficacy study of Russian recombinant tissue plazminogen activator Revelisa in patients with myocardial infarction. Terapiya. 2019;2:42-56. (In Russ.). https://doi.org/10.18565/therapy.2019.2.42-57
  24. Soldatov MA, Klimov LV, Tolmachev AP, et al. Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12-2):1-8. (In Russ.). https://doi.org/10.17116/jnevro202212212242
  25. Murtazalieva DM, Zakar’yaeva AR, Soshina TD, et al. Experience of using a Russian alteplase product as thrombolytic therapy in patients with ischemic stroke in routine practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8-2):1-5. (In Russ.). https://doi.org/10.17116/jnevro202312308255
  26. Marchenko SV, Hil UV, Hil IG. Comparative characteristics of the efficacy and safety of the original alteplase and its complete biosimilar in the treatment of ischemic stroke in real clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry 2024;124(3-2):1-6. (In Russ.). https://doi.org/10.17116/jnevro202412403249
  27. Shamalov NA, Khasanova DR, Marchenko SV, et al. Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study. Neurology, Neuropsychiatry, Psychosomatics. 2025;17(1):57-66. (In Russ.). https://doi.org/10.14412/2074-2711-2025-1-57-66
  28. Clinical guidelines «Ischemic stroke and transient ischemic attack in adults». 2021. Accessed Sept 24, 2025 (In Russ.). https://cr.minzdrav.gov.ru/archive
  29. Khasanova DR, Kalinin MN, Ibatullin MM, Rakhimov ISh. The haemorrhagic transformation of cerebral infarction: classification, pathogenesis, predictors and effect on the functional outcome. Annals of clinical and experimental neurology 2019;13(2):47-59. (In Russ.). https://doi.org/10.25692/ACEN.2019.2.6
  30. Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(12):e343-e361. https://doi.org/10.1161/STR.0000000000000152
  31. Shamalov NA. Reperfusion therapy for ischemic stroke in the Russian Federation: Problems and promises. Neurology, Neuropsychiatry, Psychosomatics.2014;6(2S):15-22. (In Russ.). https://doi.org/10.14412/2074-2711-2014-2S-15-22
  32. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282.  https://doi.org/10.1016/S0140-6736(07)60149-4
  33. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303-1309. https://doi.org/10.1016/S0140-6736(08)61339-2
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.